Zevra Therapeutics (ZVRA) Return on Capital Employed (2015 - 2026)
Zevra Therapeutics (ZVRA) posted Return on Capital Employed of 2.32% for Q1 2026, up 91.24% on a QoQ basis from 26.43% in Q4 2025, and up 4611.0% year-over-year from 0.05% in Q1 2025.
Zevra Therapeutics (ZVRA) Return on Capital Employed (2015 - 2026) Analysis & Trends
Zevra Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 2.32% for Q1 2026.
- Quarterly Return on Capital Employed rose 4611.0% year-over-year to 2.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.32% (up 4611.0% YoY) and the FY2025 annual result came in at 32.76%, up 2888.0% from the prior year.
- Return on Capital Employed was 2.32% for Q1 2026 at Zevra Therapeutics, up from 26.43% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2.32% in Q1 2026 and bottomed at 64.98% in Q3 2024.
- A 5-year average of 45.41% and a median of 45.97% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 6223 bps — and 2026, when it jumped 4611 bps.
- Zevra Therapeutics' Return on Capital Employed stood at 38.69% in 2022, then tumbled by 56 bps to 60.54% in 2023, then climbed by 5 bps to 57.7% in 2024, then jumped by 54 bps to 26.43% in 2025, then soared by 91 bps to 2.32% in 2026.
- Business Quant data shows ZVRA's Return on Capital Employed at 2.32% in Q1 2026, 26.43% in Q4 2025, and 36.98% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | -2.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.32% |
| Dec 31, 2025 | -26.43% |
| Sep 30, 2025 | -36.98% |
| Jun 30, 2025 | -64.16% |
| Mar 31, 2025 | -48.42% |
| Dec 31, 2024 | -57.70% |
| Sep 30, 2024 | -64.98% |
| Jun 30, 2024 | -63.72% |
| Mar 31, 2024 | -43.41% |
| Dec 31, 2023 | -60.54% |
| Sep 30, 2023 | -43.53% |
| Dec 31, 2022 | -38.69% |
| Sep 30, 2022 | -30.27% |
| Jun 30, 2022 | -54.53% |
| Dec 31, 2021 | 5.91% |
| Sep 30, 2021 | 5.48% |
| Jun 30, 2021 | 7.70% |
| Mar 31, 2021 | 11.00% |
| Dec 31, 2020 | -152.81% |
| Sep 30, 2020 | 11.53% |